BrainStorm Cell Therapeutics Inc (BCLI)

[Fmello]

Zack's is giving a stock valuation of $33 per share.

The countdown is on to the topline data release for the Phase 3 ALS trial, with those results expected before the end of November 2020. Even with the great run the stock has had since its recent lows in March 2020, we continue to view the shares as undervalued as we currently forecast peak sales for NurOwn® of >$1 billion in ALS, >$500 million in MS, and >$2 billion in Alzheimer’s disease. We recently made a slight change to our model, in which we decreased the discount rate from 17% to 13%, and combined with the recent financing activity has resulted in an increase to our valuation to $33 per share.

https://scr.zacks.com/News/Press-Releases/Press-Release-Details/2020/BCLI-Phase-3-ALS-Data-Expected-by-the-End-of-November-2020-article/default.aspx